Practical answers

Practical Answers

By Peter Lin/ On 19 Mar, 2026

China Invention Patent vs Utility Model: Which One Fits Your Situation?

Foreign applicants often assume that a “real patent” strategy in China means filing only an invention patent. That assumption is understandable. In many jurisdictions, clients are taught to think primarily in terms of one major patent route. But China gives foreign applicants a more practical range of filing choices, and one of the most misunderstood is the utility model. The result is that some companies underuse a tool that could have helped them, while others treat it as a shortcut without understanding its limits. The Real Question The real question is not: “Which one is better in general?” The real question is: “What kind of product, timeline, disclosure stage, and enforcement need do I have in China right now?” That is what should determine whether invention, utility model, or a combined strategy makes sense. What Foreign Applicants Often Miss Many foreign clients miss two things at once. First, they assume the invention patent is always the only serious route worth discussing. Second, they underestimate how useful a faster, narrower, more practical filing can be when the commercial pressure is immediate. This matters especially for:hardware products; consumer devices; tools and fixtures; structural improvements; products already moving toward manufacturing; situations where speed matters almost as much as long-term scope.A Simple Working Difference A useful practical distinction is this: Invention patent Best when the core value lies in the technical solution itself, and the applicant wants stronger long-term protection logic even if the path is slower and more demanding. Utility model Best when the protectable value lies in the structure or configuration of a product and the applicant needs a faster and often more commercially tactical filing route. That does not make utility model “less serious.” It makes it different. When an Invention Patent Often Makes Sense An invention patent route often deserves serious attention when:the core value lies in a deeper technical concept; the business wants a stronger long-term prosecution path; the product will remain important over a longer market cycle; the applicant can tolerate a more demanding route; the invention is not just a visible structural tweak.For many software-adjacent, algorithm-heavy, chemistry, materials, process, or more technical device matters, invention filing remains the main path to consider. When a Utility Model Often Makes Sense A utility model often deserves attention when:the protectable value is embodied in product structure; the product is hardware-oriented; manufacturing exposure is approaching quickly; the business needs earlier practical leverage; the commercial life cycle may reward speed.This is one reason utility models often matter in China-facing supply chain situations. By the time many foreign teams begin thinking seriously about China, they are already close to supplier engagement, sample work, tooling, or production transition. At that stage, a fast and practical route can matter more than they originally assumed. When Filing Both Can Make Sense Some foreign applicants are surprised to learn that the right answer may not be “either/or.” A dual-track approach can make sense when:the product has meaningful structural protectability now; the applicant also wants a longer-term invention route; the business needs earlier tactical protection while preserving a fuller prosecution path.This is not appropriate for every case. But in the right matter, it can create a much more realistic China protection posture than a one-route-only mindset. What Usually Matters First Here is the sequence I usually suggest clients think through. 1. What exactly is protectable? Is the protectable value in deep technical content, visible product structure, design appearance, or some combination? 2. How close are you to disclosure or manufacturing? If supplier-stage exposure is near, the timeline question becomes more important. 3. What does your commercial window look like? Some products need practical leverage earlier. Some justify a longer and heavier protection route. 4. Is the route being chosen in isolation? Patent route decisions are weaker when they ignore factory timing, contract protection, or brand exposure. How This Connects to Manufacturing and Contracts Patent route decisions in China often get mishandled because they are discussed as if they live inside a filing silo. In practice, the patent question often overlaps with:supplier disclosure timing; tooling development; production launch sequencing; contract protection; China trademark visibility if the product is already branded.If you are already near Chinese factory conversations, the patent route should not be discussed alone. It may need to be coordinated with China NNN & OEM Agreements. If your filing involves more complex route or prosecution judgment, China Patent Attorney may be the better next page. If you want the practical filing route overview first, start with China Patent Filing Support. The Wrong Way to Decide The wrong way to decide is to reduce the issue to one sentence like:“Utility model is cheap, so let’s do that.” “Invention is the serious one, so let’s ignore utility model.” “We can wait until after manufacturing starts.” “We only need to think about the filing form.”Those are all examples of treating China filing as paperwork instead of strategy. A Better First-Step Discussion A better first-step discussion asks:What are we actually trying to protect? How quickly does exposure increase if we wait? Is a dual route worth considering? Does our manufacturing timeline change what is practical? Are we trying to save filing cost in a way that creates bigger downstream risk?That is usually the conversation that produces the right route. Frequently Asked Questions Is a utility model always the faster route? It is often used where speed matters, but speed alone should not decide the filing route. The product type, claim focus, and commercial goal still matter. Is an invention patent always stronger? Not in every practical business sense. It may be stronger for some objectives, but it can still be the wrong first move if the timing, product structure, or commercial reality points elsewhere. Should I discuss this before talking to Chinese suppliers? Very often, yes. If supplier disclosure is close, route timing matters more than many foreign applicants realize. Final Thought The choice between invention patent and utility model in China is not a prestige question. It is a sequencing and fit question. The best route is the one that matches your product, your exposure timing, and your real business need in China — not the one that sounds most familiar from another jurisdiction. If you are at that stage now, start with China Patent Filing Support, or review China Patent Attorney if you need a more strategy-heavy discussion.

Practical Answers

By Peter Lin/ On 19 Mar, 2026

Do I Need a China Trademark Before I Talk to a Manufacturer?

A surprising number of foreign brands begin talking to suppliers, packaging vendors, sourcing agents, or manufacturers in China before they have taken even a basic China trademark step. That usually feels efficient at first. The team wants to move. Samples need to be discussed. Packaging language needs to be tested. Product names start appearing in decks, emails, mockups, and quotations. Everyone tells themselves the trademark can be handled “once things get more serious.” In many cases, that is exactly backwards. The Real Question The question is not whether you need a China trademark eventually. If China matters commercially, that answer is usually yes. The real question is: Do you need at least some China trademark thinking before your brand begins circulating through manufacturing, sourcing, packaging, or go-to-market conversations? For many foreign brands, the answer is also yes. That does not mean every business must file immediately in all classes before any contact with China. But it does mean that brand exposure often starts earlier than founders expect — and earlier than many teams budget for. Why This Issue Starts Earlier Than People Think Many foreign clients assume trademark risk begins when they officially launch in China. In practice, it can begin much earlier:when the product name appears in supplier emails; when packaging artwork is shared for quotation; when a logo file is circulated for printing or molding; when a distributor or factory sees the English mark and starts asking whether there is a Chinese name; when the team uses the brand publicly in trade channels connected to China.At that point, your brand is no longer living only inside your own internal business. It has entered a wider commercial environment. What Foreign Brands Often Miss The most common mistake is treating manufacturing and trademark protection as separate phases. A brand owner may think: “We are not launching yet. We are only sourcing.” But if your supplier relationships, packaging references, product labels, mockup files, or Chinese market plans are already tied to a specific brand identity, then the trademark question has already started. And once a brand becomes commercially visible in China-facing conversations, waiting may stop being a neutral choice. What Usually Matters First Not every case needs the same first move. Here is a practical way to think about it. If you already have a final English brand name Do not assume that is enough. Ask whether the English mark itself should be reviewed for China filing, and whether a Chinese name strategy should begin now rather than later. If you are sharing packaging or product branding with suppliers You are already beyond pure “internal planning.” At minimum, you should assess filing timing and subclass coverage before broader exposure grows. If you do not yet know your final China-facing brand structure That is exactly why a review is useful. It is often better to clarify the route before a name begins spreading informally. If you are in a hurry That is not unusual. But speed is a reason to make the right first move, not a reason to skip it. Why Supplier Conversations Can Increase Brand Risk A supplier relationship is not automatically a trademark problem. But it can become one quickly because suppliers often sit close to other parts of the market:packaging vendors; other factories; distributors; sourcing intermediaries; logistics and customs-facing service providers.The more your branding circulates, the less control you have over where and how it is seen. That is why contract protection alone is not enough. A supplier-stage document may help reduce disclosure and misuse risk, but it does not replace registration strategy. If your issue is on the contract side, review China NNN & OEM Agreements. If your issue is on the brand side, the right next page is China Trademark. Why China Trademark Work Is Not Just “File One Mark, One Class” Another mistake foreign brands make is thinking this issue is simply about getting one certificate. In real work, early China trademark decisions often involve:whether the English mark should be filed as-is; whether a Chinese name should be created now; how subclass logic affects practical coverage; whether the current manufacturing stage justifies broader or narrower action; whether filing should be coordinated with product launch timing and supplier exposure.That is why a practical first review is often more valuable than rushing blindly into a filing that feels cheap but solves the wrong problem. How This Connects to Patents and Contracts For many physical-product businesses, the brand question is not isolated. Contract layer If you are about to disclose product details to a Chinese factory, you may also need contract-side protection, especially around non-use, non-disclosure, and non-circumvention. That is a different layer from trademark registration, but the timing often overlaps. Patent layer If the protectable value is also in product structure or function, the patent timing question may need to be addressed before deeper supplier disclosure. In that case, China Patent Filing Support becomes relevant too. The practical point is simple: If China supplier conversations are starting, your brand, product, and contract exposure may all be starting together. What a Good First Step Looks Like A good first step is usually not “file everything immediately” or “do nothing until launch.” It is usually a structured first review that asks:What brand is actually in use? Is there a likely Chinese name issue? What classes and subclasses matter commercially? Has supplier-stage exposure already begun? Do contract and patent timing need to be reviewed at the same time?That is why a staged trademark entry path is often the most practical option. You can review the route through China Trademark or, if you are deciding among packaged starting points, check Pricing. Frequently Asked Questions What if I am only talking to one factory and trust them? Trust is valuable, but trust is not a substitute for structure. A factory conversation can still create wider exposure than founders expect, especially when branding appears in packaging, samples, sourcing discussions, or related vendor interactions. Do I need a filed China trademark before every supplier conversation? Not always. But you do need to know whether the conversation you are about to have is likely to create enough brand exposure that filing should no longer be postponed casually. What if I have not decided on a Chinese brand name yet? That is common. The right response is not to ignore the issue, but to decide whether Chinese naming should be part of the early brand plan. Final Thought A China trademark is not just a “market entry formality.” In many cases, it is part of the preparation work that should happen before manufacturing-side exposure expands. If your brand is about to enter supplier, packaging, or sourcing conversations tied to China, the most practical move is to review the route before the brand spreads faster than the protection around it. Start with China Trademark or Talk to Us if you want a practical first-step view.

Practical Answers

By Peter Lin/ On 19 Mar, 2026

NDA vs NNN for China: What Foreign Innovators Get Wrong

If you are preparing to talk to a Chinese supplier, the first legal document that usually comes to mind is an NDA. That instinct makes sense. In many Western business settings, an NDA is the standard first step before sharing product information, pricing assumptions, technical drawings, or supplier requirements. But China factory-side risk often does not begin with disclosure alone. It begins with what happens after disclosure: use, replication, side production, customer bypass, tooling misuse, and commercial workarounds that a standard NDA was never built to stop. That is where many foreign founders and brand owners misjudge the situation. They believe they are “covered” because they sent over a familiar English-language NDA. In reality, the document may be too narrow, too soft, or too disconnected from the actual way manufacturing risk develops in China. The Real Question The real question is not whether an NDA is “good” or “bad.” The better question is: What exactly are you trying to stop before you start talking to a Chinese supplier? If you are only worried about pure disclosure, an NDA sounds logical. But most foreign companies are worried about more than that. They are also worried about:a supplier using what it learns to make similar products for others; a supplier bypassing them to reach distributors, customers, or sourcing contacts; a factory treating their product information as commercially reusable know-how; a factory-side relationship moving faster than the brand, patent, or contract structure protecting it.That is why the conversation has to move beyond “Do I have an NDA?” and toward “Have I actually locked down the right risks?” What People Often Miss Foreign innovators usually underestimate how quickly one early supplier conversation can create multiple kinds of exposure at once. You may be discussing:technical features that should have been patent-filed first; product branding that should already be protected as a China trademark; samples, drawings, BOMs, molds, or production tolerances that should not be reused; supply chain contacts that should not be cut around.In other words, your supplier-stage problem is often not just a confidentiality problem. It is a commercial control problem. That is why an NNN agreement is usually the more useful concept in China-facing supplier work. It is designed around three practical concerns:Non-disclosure — do not disclose what I share; Non-use — do not use what I share for your own benefit or for third parties; Non-circumvention — do not go around me to reach the relationships, channels, or commercial structure behind the project.That still does not make NNN a magic document. It simply makes it a more realistic starting point than a generic NDA when the real risk is factory-side misuse. Why a Standard NDA Often Falls Short A standard NDA often fails in one of four ways. 1. It focuses too narrowly on secrecy Many NDAs are drafted as if the only real danger is public disclosure. But Chinese manufacturing risk frequently involves private misuse, not public publication. 2. It does not address commercial bypass behavior A supplier may not “leak” your information publicly and may still create serious damage by using it in competing production, parallel supply, or direct customer contact. 3. It is not built for China-facing enforceability A contract can look polished and still be weak in practice if it does not fit the enforcement reality you are actually entering. 4. It is disconnected from your IP timing If you have not handled your China trademark plan or your patent filing sequence, even a better contract may still leave you exposed. What Usually Matters First Most readers do not need a long legal lecture. They need a sequence. Here is the practical sequence I usually recommend: If your issue is mainly about supplier conversations Start with the contract structure first. If you are about to send specifications, CAD files, component logic, or commercial terms, do not wait until “later” to think about document control. If your issue is mainly about product protection Check whether a China patent filing should happen before deeper disclosure. If your protectable value is in structure, function, or product design, timing matters. If your issue is mainly about brand exposure Ask whether your China trademark strategy is already in place. If your brand name, logo, or Chinese name may surface in supplier discussions, do not assume you can safely defer trademark action. If your issue is mainly about manufacturing scale-up Move beyond a first-stage NNN and think about whether you now need a fuller OEM or manufacturing agreement. How This Connects to Trademarks, Patents, or Contracts This is the part many general contract providers miss. A China-facing supplier document should not be treated as a standalone legal paper detached from the rest of your IP posture. Trademark connection If your factory, packaging vendor, or sourcing contacts see your brand before you have a serious China trademark plan, the contract is trying to compensate for a registration gap. That is usually not the best position to be in. If branding is already in play, review your route through China Trademark before assuming contract language is enough. Patent connection If the sensitive value lies in the product itself — structure, mechanism, hardware design, or technical solution — the timing of patent action may matter just as much as the wording of the supplier agreement. If your issue is not just confidentiality, but product protectability, look at China Patent Filing Support before supplier disclosure becomes your first irreversible move. Contract connection If you are still in the pre-supplier or early supplier stage, China NNN & OEM Agreements is usually the best next page to review. It is where the factory-side protection logic becomes more specific. When an NNN Is Still Not Enough An NNN agreement is often a first-stage document, not the final one. Once you move deeper into production, you may need a fuller structure covering issues such as:tooling and mold ownership; production exclusivity or restrictions; quality control obligations; subcontracting limits; inspection rights; product ownership and leftover inventory; post-termination handling; practical breach consequences.At that point, the right question is no longer “Do I need an NDA or NNN?” It becomes: Do I now need a full manufacturing agreement with the right IP logic built in? Frequently Asked Questions Is an NDA completely useless for China? Not necessarily. In some early commercial settings, an NDA may still have a limited signaling role. The problem is not that every NDA is worthless. The problem is that many foreign companies mistake a familiar NDA for sufficient factory-stage protection. Do I always need an NNN before talking to a supplier? Not every conversation carries the same risk. But if the conversation involves meaningful product, sourcing, pricing, customer, tooling, or production information, it is often risky to treat contract protection as an afterthought. Should I handle the trademark first or the supplier agreement first? It depends on what is about to be exposed first. In many real matters, both need to move together. That is why a coordinated review is usually better than a narrow one-document answer. Final Thought The biggest mistake foreign innovators make is not choosing the “wrong acronym.” It is assuming one familiar document solves a multi-layered China entry problem. If you are about to speak with a Chinese supplier, the practical question is not just “Do I have an NDA?” It is whether your contract layer, trademark layer, and patent timing are aligned before exposure starts. If you are already at that stage, review China NNN & OEM Agreements or Talk to Us and map the risk before it grows into something more expensive.

Practical Answers

By Peter Lin/ On 22 Dec, 2025

If a Translation Error Narrows Your Patent in China — Will CNIPA Be Sympathetic?

Here is a scenario I've seen damage Chinese patent portfolios more than once: A foreign company enters China's national phase via PCT. The Chinese translation is done quickly, under deadline pressure, without sufficient technical review. A single term — a materials specification, a functional description, a dimensional range — is translated too narrowly. The original PCT application covers "metal alloy"; the Chinese translation reads "aluminum alloy." Now the examiner works with the Chinese text. The granted patent is limited to aluminum alloy. The company's actual product uses a titanium alloy. The question everyone asks afterward: Will CNIPA let us correct it? The honest answer: sometimes, but the standard is strict and the window is short. How CNIPA Treats Translation as the Binding Text This is the foundational issue. Under China's patent system, the Chinese translation you submit at national phase entry becomes the operative text for examination purposes. CNIPA does not conduct examination on the original English (or other language) PCT application. The Chinese document is what examiners read, cite, and base their assessment on. This is different from some other jurisdictions where the original application remains the reference. In China, if there is ambiguity or conflict between the original PCT filing and the Chinese translation, the Chinese translation governs — unless you successfully obtain a correction. The Correction Mechanism: What Exists China's Implementing Regulations do provide a mechanism for correcting errors in translations submitted at national phase entry. The relevant provision allows an applicant to request correction of an obvious translation error when:The mistake is clearly an error — not a judgment call or intentional drafting choice, but an actual mistranslation. The correction would restore the Chinese text to accurately reflect the original PCT application. The correction does not introduce subject matter that goes beyond the original PCT application as a whole.The third condition is the critical one. If the mistranslation was a narrowing of the original PCT disclosure, correcting it should not violate the no-new-matter rule — because you're restoring the original scope, not adding something new. Where the Process Gets Difficult In practice, "obvious translation error" is interpreted narrowly by CNIPA examiners. Here is where applicants run into problems: The error is arguable, not obvious. If there are two plausible Chinese translations of a term and one happens to be narrower, CNIPA may view the narrower translation as a reasonable choice rather than a clear error. "Reasonable choice" is not correctable. "Clear mistranslation" is. The correction window has passed. CNIPA has a time limit for requesting translation corrections. Applicants who discover a translation problem late in prosecution — or after grant — have very limited options. Post-grant correction is even harder. The correction requires supporting evidence. To successfully correct a translation error, you typically need to provide the original PCT text (in the original language), a side-by-side comparison, and often a declaration or explanation showing that the Chinese translator deviated from the source. Without this documentation, the request is unlikely to succeed. Is CNIPA Sympathetic? Straightforwardly: less than you might hope. The Chinese China Patent system is procedural and examiners work within defined standards. They are not adversarial, but they are also not inclined to exercise generous discretion where the rules are not clearly on your side. CNIPA will review a well-documented correction request for an obvious error fairly. What it will not do is accept borderline arguments, overlook timing requirements, or allow corrections that stretch into new matter territory even slightly. The applicants who succeed with correction requests are those who:Identify the error early (before or during examination, not after grant) Have kept the original-language PCT application and the Chinese translation in a form that allows direct comparison Can demonstrate the error is unambiguous — not one of two reasonable interpretations Work with a China Patent Attorney who understands CNIPA's correction procedure and documentation requirementsThe Real Lesson: Prevention Over Remedy Every practitioner who has been through a translation correction request with CNIPA knows the same thing: the process is difficult, expensive, and uncertain. Even a successful correction takes months and significant attorney time. An unsuccessful correction leaves you with the narrowed patent permanently. The correct response to translation risk is to prevent it, not to plan for correction. Here are the specific linguistic categories where narrowing errors most commonly occur in Chinese patent translation: Functional language. English claim language like "configured to" or "operable to" has no direct Chinese equivalent with the same legal weight. Translators sometimes substitute 用于 (used for) which can be read as a use limitation rather than a structural feature. This subtly narrows scope. Numerical ranges. Ranges like "between 10 and 50 mm" or "at least 80%" are sometimes rendered with the wrong boundary interpretation in Chinese (including or excluding endpoints). These discrepancies compound in prosecution when examiners apply the Chinese text literally. Material and component generalizations. "Conductive material" translated as "金属" (metal) instead of "导电材料" (conductive material) — this exact type of narrowing gives rise to the titanium alloy scenario described above. In chemistry and materials patents, every noun is a potential claim scope trap. Method claim verbs. Verbs describing process steps — especially in pharma, biotech, and software — often have multiple Chinese translations with different levels of specificity. The broader English verb may not have a direct Chinese cognate. The practical prevention checklist:Allocate 10+ business days for complex specifications, with technical review Have a bilingual patent professional review the Chinese translation of your key claims before submission Work with a translation provider that has subject-matter expertise, not just general technical translators Review the translation yourself if you have Chinese language capability — at minimum, run the independent claims through a reverse translation and compareConcerned about translation quality in your China patent applications? Our China Patent team reviews PCT translations before national phase entry and handles CNIPA correction procedures when needed. Speak with a China Patent Attorney about protecting your claim scope from the start.

Practical Answers

By Peter Lin/ On 17 Dec, 2025

A Simple Way to Cut China Patent Costs When Using PCT — Without Giving Up Protection

Let me say something directly: most foreign companies entering China via PCT are paying more for their Chinese patents than they need to. Not because of unfair fees, and not because their technology is especially complex — but because nobody has walked them through the specific cost levers that exist in this system. This is a practical guide to those levers. Understanding Where China Patent Costs Come From Before you can cut costs intelligently, you need to know where they go. For a typical China Patent application entering via PCT, the main cost buckets are:Official CNIPA fees: Filing fees, claim surcharges, examination fees Translation fees: Chinese translation of the full specification, claims, and abstract Professional services: Attorney or agent fees for formalities, claim strategy, and prosecution management Office action responses: Costs that arise if CNIPA examiner raises objections after filingThe first three are largely determined by what you submit at national phase entry. The fourth depends on how well you handled the first three. Lever 1: Reduce Claims to 10 or Below This is the single most effective cost reduction available to most applicants, and it's often overlooked because it requires a strategic decision rather than just a procedural one. China charges an extra fee for every claim beyond the first ten. At the current CNIPA fee schedule, each additional claim costs RMB 150 extra in filing fees — and this is per claim, per application, at entry. For an application with 25 claims, that's RMB 2,250 in surcharges before prosecution even begins. Across a portfolio of 10 applications, you're looking at RMB 22,500 in preventable costs. More importantly: reducing claims forces a useful discipline. Which 10 claims actually capture what you need to protect in China? That forced prioritization almost always produces a stronger prosecution strategy. Work with a China Patent Attorney to review which claims are genuinely necessary for Chinese market protection and which are redundant or commercially irrelevant for this jurisdiction. Lever 2: Use the International Search Report to Pre-Empt Office Actions One of the underutilized advantages of PCT is that you receive an International Search Report (ISR) — typically by month 16 from your priority date — that identifies prior art relevant to your claims. Most applicants read this report once and file it away. A smarter approach: use the ISR to narrow or differentiate your claims before China national phase entry. If the ISR identified prior art that your current independent claim reads on, addressing that in your Chinese claim set before entry means you avoid the same objection being raised by a CNIPA examiner six months into prosecution — which costs you an office action response fee, attorney time, and months of delay. Pre-emptive amendment based on ISR findings is one of the clearest, lowest-cost interventions available before the 30-month deadline. Lever 3: Trim the Specification Length Where Possible China's official fees include a per-page component above a base threshold. More consequentially, translation costs are purely volume-driven. Review your international specification with a China-specific lens:Are there multiple detailed examples that describe the same embodiment with minor variations? Consolidating these reduces page count without affecting claim support. Are there sections discussing prior art in excessive detail? These may be necessary for US prosecution but add translation cost in China. Are there drawings that replicate each other with minimal difference? Each drawing page has a cost.Trimming even 20–30% of specification length can produce meaningful savings, especially for large mechanical or pharma filings where descriptions commonly run 100+ pages. Lever 4: Sequence Your Portfolio Entry Strategically If you have multiple PCT applications approaching the 30-month deadline in the same period, the sequence and grouping of national phase entries matters. Some applicants enter all applications simultaneously, paying a large lump sum of fees and translation costs in a short window. Others sequence entries across 3–6 months to smooth cash flow and allow claim review on each application before committing. More importantly: if two related applications in your portfolio cover overlapping technology, entering them simultaneously allows a single attorney review session to address both claim strategies — reducing professional fee overhead compared to treating each in isolation. What You Don't Have to Give Up The goal here is cost efficiency, not weakened protection. A 10-claim application with three tight independent claims and seven well-structured dependent claims can be more defensible in Chinese courts and licensing contexts than a sprawling 30-claim application that's never been tested. Chinese IP enforcement increasingly focuses on specific, clean claims. Clarity and focus are assets in China's court system and in licensing negotiations — not liabilities.Want a pre-entry cost review for your PCT applications? Our China Patent team provides claim strategy and cost analysis before your 30-month deadline. Speak with a China Patent Attorney today.

Practical Answers

By Peter Lin/ On 15 Dec, 2025

How Much Can You Really Amend Claims When Entering China via PCT?

One of the most common questions I hear from foreign inventors entering China via PCT is: "I want to adjust my claims before the Chinese prosecution starts — how much can I actually change?" The honest answer is: more than you think in terms of scope reduction, but far less than you think in terms of new content. And the boundary between the two is where applicants get into trouble. What the Rules Say When entering China's national phase via PCT, you are technically allowed to amend your claims. CNIPA accepts amendments at national phase entry under China's Patent Law and the Implementing Regulations. But those amendments are subject to a fundamental constraint: No amendment may introduce subject matter that goes beyond the original disclosure — meaning the content of the international application as filed. This rule appears in the Chinese Patent Law broadly, and CNIPA examiners apply it consistently. The relevant standard is "beyond the original disclosure," not just "beyond the original claims." That distinction matters significantly. What You Can Do: The Permitted Range Within the no-new-matter rule, the following types of amendments are generally permitted: Narrow the independent claims. You can import limitations from your dependent claims into an independent claim, making it narrower and more specific. This is the most common and useful type of amendment at national phase entry. Delete claims entirely. Removing claims — whether to reduce fees (claims beyond 10 are surcharged) or to simplify prosecution — is permitted. You cannot, however, re-add them later without going through a formal amendment process. Combine dependent claims into a new independent claim. If a combination of features from two dependent claims is fully supported by your specification, you can combine them into a new independent claim. This is useful for creating a stronger fallback position. Correct obvious translation errors. If your Chinese translation contains an error that results in a narrower scope compared to the original PCT application, you can request correction — but only if the correction is directly and unambiguously supported by the original international filing. What You Cannot Do: The Hard Line Add features not in the original specification. If a feature was never described anywhere in your international application — not in the claims, not in the description, not in the drawings — you cannot add it to your claims at national phase entry. CNIPA will reject the amendment as introducing new matter. Broaden claim scope beyond what was disclosed. You cannot broaden an independent claim to cover subject matter that was described only as a narrower sub-case in the original application. For example, if your specification only describes an embodiment using "copper wire," you generally cannot amend the claim to read "conductive wire." Import content from prior art or external sources. Even if something is technically compatible with your invention, it must be described in the original application to be incorporated into claims. The Common Mistake: Over-Relying on What's in the Specification I see this pattern regularly: an applicant wants to amend their China Patent claims to add a feature that was mentioned in the background section or in a general statement of advantage — but never specifically claimed or described as a component of the invention. CNIPA examiners draw a tight circle around "original disclosure." A feature in the background section is not always treated as part of your invention disclosure. A general admissibility statement ("the invention may also include...") without a specific embodiment is often not enough to support a claim amendment. The lesson: your specification's disclosure quality, written at the time of the original PCT filing, determines your amendment latitude in China — often 28+ months later. Practical Strategy: Front-Load Your Disclosure The best way to maximize your amendment options in China is to draft your international application with China specifically in mind:Include multiple specific embodiments in the description, not just one or two. Write out dependent claims carefully — each one represents a fallback position you can later elevate into an independent claim. Avoid overly narrow "examples" without broader claim support language.A China Patent Attorney can review your existing PCT application and identify which amendments are genuinely available to you before national phase entry — and which wishlist items are off the table. What About Article 34 Amendments? Before entering the national phase, you may also have used PCT Article 34 to request preliminary examination and amend claims internationally. Those amendments, if already incorporated into your PCT application, become the new baseline for China national phase entry. However, China is not obligated to accept them if they introduced new matter by PCT standards — and CNIPA performs its own assessment.Need to review your PCT application before China national phase entry? Our China Patent specialists can audit your pending PCT applications and advise on amendment strategy. Or speak directly with a China Patent Attorney about your specific filing.

Practical Answers

By Peter Lin/ On 12 Dec, 2025

Adult Products Often Get Rejected for Patents in China—Why?

China's Patent Scene: Huge Opportunities, but Article 5 is a Hidden Minefield China's paAdult productsploding—global $50B by 2027 (Statista), with China leading manufacturing （Dongguan & Shenzhen）. Yet Article 5 of the Patent Law is a silent killer, blocking grants for inventions seen as violating "social morality" or public interest. Designs saw a 15% rejection spike in 2024 due to visual cues, but utility and invention patents can stay steady if drafted right. The issue? Examiners tag products as "non-medical artificial sexual substitutes," sparking morality checks. From my examiner chats and database dives, if descriptions scream "intimate," initial reviews flop. Article content Kegel Exercises: Your "Medical Shield" to Bypass Article 5 How to flip it? Kegel exercises are your secret weapon. Developed by Dr. Arnold Kegel in the 1940s, these pelvic floor workouts help millions with incontinence, postpartum recovery, and quality of life (PubMed studies). In patents, a line like "vibration modes simulate Kegel contractions for muscle strengthening" shifts from "toy" to "health aid." Why? The 2023 guidelines say non-medical substitutes violate morals; Kegels provide real medical evidence (GB/T 14895-2010 standard), and examiners nod at that. In a case I handled, this turned a "no" into approval—but don't fake it; unsubstantiated claims risk fines. Article content patent illustration Drafting Magic: Lessons from a Smooth Success Case Drafting is the real art. Take CN223666103U, an "insertable electric massager" granted December 2025 without issues—just 10 months. It nailed it by focusing on "vibration mode indicators" over intimacy. CNIPA data shows medical-framed patents hit 85% approval in 2024, vs. 40% for pure adult ones. Here's their techniques vs. pitfalls I've fixed Article content This echoes trends: 2023 guidelines stress public acceptance—Taobao sales or Shanghai expos aren't "immoral." But controversies persist: Unproven health claims lead to rejections. Examiners aren't anti-innovation; they just need proof it's beneficial, not boundary-pushing. For Global Players: Stack US/EU Patents For global players, stack US/EU patents—USPTO's lenient on health claims, perfect for Amazon enforcement. Faced challenges in sensitive tech patents? Share below—I'd love your stories! #PatentStrategy #AdultWellness #ChinaIP #KegelInnovation #EntrepreneurJourney Key Citations: China National Intellectual Property Administration (CNIPA) Database Statista Adult Wellness Market Report PubMed on Kegel Exercises Beijing IP Court Case (2019) Jing 73 Xing Chu 3870 2023 Patent Examination Guidelines For more article, visit our Linkdedin newsletter: https://www.linkedin.com/newsletters/china-ip-gateway-7392039659566153728/

Practical Answers

By Peter Lin/ On 12 Dec, 2025

PCT Patent Entry into China: A Cost Lock-In Mechanism Many Applicants Overlook

There is a moment, usually around month 28 or 29 of your PCT application's life, when your China IP strategy becomes a cost reality. The application that started as an idea — and grew through drafting, international search, and maybe some Article 19 amendments — now has to become a paid-up Chinese patent prosecution. What many applicants find surprising is how much of that cost was already locked in by decisions made much earlier. This is what I call the cost lock-in mechanism of PCT entry into China. What Gets Locked In at National Phase Entry When you enter China's national phase, CNIPA's official fees are calculated based on the application as it stands at entry. Specifically: 1. Claim count. China charges a per-claim surcharge for every claim beyond the first ten. If your PCT application has 25 claims, you're paying surcharges on 15 of them upfront — before a single examination action. This is calculated from the claims in your Chinese translation at the time of national phase entry. 2. Page count for specification. China's official fee structure also includes charges based on application length above a base threshold. A long international specification — common in US and European biotech or software filings — translates to elevated fees. 3. Translation volume. Unlike most Western patent offices, CNIPA requires a complete Chinese translation of your entire application at national phase entry. The word count in your international specification drives translation costs directly. A 200-page biotech specification translated at professional patent rates is a significant line item. 4. Number of independent claims. Prosecution strategy in China often hinges on independent claims, and CNIPA's fee structure treats them differently from dependent claims. Applicants with multiple independent claims per claim category (product + method + use) face compounded costs. Why "Lock-In" Happens in Practice These cost drivers are not surprising in isolation. What makes them a lock-in mechanism is that they were all set at the time your international PCT application was drafted — often 18 to 28 months before you ever think about China costs. The original PCT drafter may have been a US firm optimizing for a large US claim set. The specification may be 150 pages because that's what a US biotech application requires. The claims may number 30 because that's what a US prosecution strategy demands. None of that is wrong for the US. But entering China's national phase with that original application, unchanged, means you're paying for a US-optimized filing in a system with a very different fee structure. The Three Levers You Can Still Pull Even though costs are largely locked in by the original application, you do have options to reduce them — if you act before national phase entry. Lever 1: Amend claims before entry. Under PCT provisions and China's national phase rules, you can amend your claim set when entering the national phase. Reducing from 25 to 10 claims before filing the Chinese translation eliminates surcharges on 15 claims from day one. Work with a China Patent Attorney to identify which claims are commercially necessary in China and which are redundant for your specific enforcement context. Lever 2: Trim the specification. If there are entire sections of your specification that are irrelevant to your China commercial strategy — detailed manufacturing examples for processes you don't use in China, regulatory guidance for systems not sold there — you may be able to reduce the document length without affecting claim support. This is technically sensitive work and needs expert review, but can materially reduce translation and page-count fees. Lever 3: Time your filing carefully. CNIPA applies fee rates based on the filing date. Fee schedules are periodically updated. While this is not always a controllable variable, large multinationals with portfolios sometimes time batch filings to a known fee period. A Cost Estimate to Make This Concrete For a typical mechanical or hardware China Patent application entering via PCT with 20 claims and a 50-page specification, you're typically looking at:Official filing fee: ~RMB 950 base Claim surcharges (10 claims over base × RMB 150): RMB 1,500 Translation (50 pages × professional rate): RMB 5,000–12,000+ Professional services (national phase formalities, claim strategy): variableCompare that to the same application trimmed to 10 claims: the surcharge line drops to zero. Over a portfolio of 20 applications entering China in a single year, that's a meaningful difference. The Upstream Solution The best time to manage China national phase costs is not at month 29. It's at the drafting stage, when you structure your PCT application with China's fee logic in mind. This doesn't mean writing a weaker patent. It means structuring claims and specifications in a way that is both strong for the US and efficient for China — not identical, but compatible.Ready to plan your China national phase entry? Our China Patent team works with applicants at every stage of the PCT timeline. Or speak with a China Patent Attorney to review your pending applications before the 30-month deadline.

Practical Answers

By Peter Lin/ On 08 Dec, 2025

Paris Convention vs. PCT in China: A Critical Difference Most Inventors Miss

Last year a Dutch hardware startup came to me eight months after filing their first patent in the Netherlands. They had a working product, a potential distributor in Shenzhen, and a growing sense that they should probably protect something in China. Eight months was still within the Paris Convention window. But when I asked whether they had a finalized Chinese translation of their specification ready to file, the answer was no — and their September launch timeline meant four months were the most they could realistically get. That conversation is where the Paris Convention versus PCT question becomes real. In theory, both routes let you claim your Netherlands filing date as your priority date in China. In practice, only one of them gave this team the time they actually needed. The two main options are the Paris Convention direct route and the PCT route, and in China specifically, there are differences that can significantly affect your cost, timeline, and final patent scope. The Basic Framework Both routes allow you to claim the priority date from your original domestic filing when you eventually file in China. That priority date matters enormously in China's first-to-file system — it determines whether you beat a competitor to protection rights.Paris Convention route: File directly in China within 12 months of your first filing date. PCT route: File an international PCT application (within 12 months of your first filing), then enter China's national phase within 30 months of your priority date.That extra 18 months the PCT route provides is not just a filing convenience. It's a strategic window that most inventors underuse. The Critical Difference Most Miss Here's what I see inventors get wrong again and again: When you file directly into China via the Paris Convention route, you must have a fully translated Chinese application ready within 12 months. That means your specification, claims, and abstract — all in Chinese — submitted together with your filing fee. For an early-stage startup, 12 months from first filing is often not enough time to finalize your design, assess the Chinese market, or arrange quality translation. The PCT route, by contrast, lets you delay that commitment. You file the international PCT application in your own language (typically English), and the Chinese translation only needs to be submitted when you enter the national phase at month 30. That's an additional 18 months to refine your claims, secure funding, or assess whether China is worth the investment. Why China Specifically Amplifies This Gap Many PCT member countries accept English filings even at national phase entry. China does not. CNIPA requires a full Chinese translation of your application at national phase entry. A poor translation can cost you claim scope — permanently. Under Chinese patent practice, if there is a discrepancy between the original PCT application and the Chinese translation, CNIPA will generally rely on the Chinese translation as the basis for examination. This makes translation quality a strategic issue, not just a clerical one. The extra time the PCT route provides lets you commission and review a professional-grade translation — rather than rushing one through in the final weeks before a 12-month Paris Convention deadline. The Trap: Assuming PCT Is Always Better PCT is not universally superior. Here's when the Paris Convention direct route makes more sense for China Patent filings:You are confident about the Chinese market now. If you have a distribution partner, manufacturing arrangement, or real commercial activity in China within 12 months, you may not need the extra time. Your technology is simple and the application is short. Translation cost and risk are proportional to specification length. A 10-page utility application translates much faster and more reliably than a 100-page biotech filing. You want to avoid PCT fees. PCT filing has its own international fee structure. If you're early-stage and China is your only international target, the direct route may be cheaper overall.What a China Patent Attorney Will Actually Tell You When I advise clients as a China Patent Attorney, this is the question I always ask first: How confident are you today about what your Chinese patent needs to protect? If the answer is "very confident, and we have a product ready to launch," the Paris Convention route is often fine. If the answer is "we think China matters but we're still refining the product," the PCT route is almost always the right choice — not for the extra protection it adds, but for the strategic flexibility it buys. A Simple Decision FrameworkSituation Recommended RouteProduct is final, China launch within 12 months Paris Convention directStill refining design or claims PCT → China national phaseMultiple countries beyond China PCT (efficiency of one filing)Budget-constrained, China only Paris Convention (lower upfront cost)Complex specification, translation risk PCT (more time for quality translation)Have questions about your China patent filing strategy? Explore our China Patent services or speak with a China Patent Attorney about whether Paris Convention or PCT is the right route for your situation.